Literature DB >> 33888794

Postoperative cognitive functions in patients with benign intracranial lesions.

Stefanie Bette1,2, Julia M Ruhland3, Benedikt Wiestler1, Melanie Barz3, Bernhard Meyer3, Claus Zimmer1, Yu-Mi Ryang3, Florian Ringel3,4, Jens Gempt5.   

Abstract

The aim of this study was to assess pre- and postoperative cognitive functions in patients who underwent surgery for benign intracranial lesions. In total, 58 patients (21 men, 37 women, mean age 51.6 years [range 24-76 years]) with benign intracranial lesions (including benign tumors and vascular lesions) and neuralgia of the trigeminal nerve were included in this prospective study. Extensive cognitive testing was used to categorize attention, memory, and executive functions. Mood and pain were assessed preoperatively (t0, mean 3.7 days before surgery), immediately after surgery/during inpatient stay (t1, mean 7.6 days after surgery), and at first outpatient check-up (t2, mean 99.5 days after surgery). All 58 patients were tested at t0 and t1, but at t2 only 24 patients were available at t2. The data were categorized as improvement/stable condition or deterioration and shown as percentages. The pre- and postoperative values of BDI-II and mood were compared by the Wilcoxon test for paired samples. Binary logistic regression analyses were performed to identify parameters influencing cognition in the subgroup of meningioma patients. Immediately after surgery (t1), the percentage of patients with improvement/stable condition was > 50% in all categories in the majority of subtests (attention: 12/14 subtests, memory: 11/13 subtests, executive functions: 6/9 subtests). Similar results were shown at t2. Mood and pain did not change significantly after surgery. Factors like age, Karnofsky performance status, and tumor volume were not shown as significant influencing factors for cognitive functions in meningioma patients. The results of this study suggest that-in contrast to neuroepithelial tumors-cognitive functions do not deteriorate after surgery of benign intracranial lesions. Further studies are necessary to evaluate the results of this study.

Entities:  

Year:  2021        PMID: 33888794     DOI: 10.1038/s41598-021-88061-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  33 in total

1.  Cognitive function as a predictor of survival in patients with recurrent malignant glioma.

Authors:  C A Meyers; K R Hess; W K Yung; V A Levin
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  Long-term impact of cognitive deficits and epilepsy on quality of life in patients with low-grade meningiomas.

Authors:  Martin L Waagemans; David van Nieuwenhuizen; Monica Dijkstra; Miriam Wumkes; Clemens M F Dirven; Sieger Leenstra; Jaap C Reijneveld; Martin Klein; Lukas J A Stalpers
Journal:  Neurosurgery       Date:  2011-07       Impact factor: 4.654

3.  Evolution of the Karnosky Performance Status throughout life in glioblastoma patients.

Authors:  Adama Sacko; Miao-Miao Hou; Michael Temgoua; Ali Alkhafaji; Athina Marantidou; Catherine Belin; Emmanuel Mandonnet; Renata Ursu; Jennifer Doridam; Irène Coman; Christine Levy-Piedbois; Antoine F Carpentier
Journal:  J Neurooncol       Date:  2015-02-21       Impact factor: 4.130

4.  Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study.

Authors:  Esther J J Habets; Linda Dirven; Ruud G Wiggenraad; Antoinette Verbeek-de Kanter; Geert J Lycklama À Nijeholt; Hanneke Zwinkels; Martin Klein; Martin J B Taphoorn
Journal:  Neuro Oncol       Date:  2015-09-18       Impact factor: 12.300

5.  Assessment of neuropsychological parameters and quality of life to evaluate outcome in patients with surgically treated supratentorial meningiomas.

Authors:  Wolfgang Krupp; Christoph Klein; Ronald Koschny; Heidrun Holland; Volker Seifert; Juergen Meixensberger
Journal:  Neurosurgery       Date:  2009-01       Impact factor: 4.654

6.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

7.  Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection.

Authors:  Kyle R Noll; Catherine Sullaway; Mateo Ziu; Jeffrey S Weinberg; Jeffrey S Wefel
Journal:  Neuro Oncol       Date:  2014-09-16       Impact factor: 12.300

Review 8.  Cognitive deficits in adult patients with brain tumours.

Authors:  Martin J B Taphoorn; Martin Klein
Journal:  Lancet Neurol       Date:  2004-03       Impact factor: 44.182

9.  Factors influencing neurocognitive function in patients with neuroepithelial tumors.

Authors:  Jens Gempt; Nicole Lange; Stefanie Bette; Sarah Charlotte Foreman; Jasmin Hernandez Cammardella; Jennifer Albertshauser; Corinna Gradtke; Niels Buchmann; Yu-Mi Ryang; Friederike Schmidt-Graf; Bernhard Meyer; Florian Ringel
Journal:  Sci Rep       Date:  2017-12-19       Impact factor: 4.379

Review 10.  Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a systematic review of neurocognitive functioning prior to anti-tumor treatment.

Authors:  Emma van Kessel; Anniek E Baumfalk; Martine J E van Zandvoort; Pierre A Robe; Tom J Snijders
Journal:  J Neurooncol       Date:  2017-05-31       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.